-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to the 2021 annual report released by pharmaceutical companies, the performance of vaccines, medical devices, medical services and other sectors has been outstanding, and the pace of approval and marketing of innovative drugs has continued to accelerate
.
And some innovative pharmaceutical companies that are losing money have narrowed or even turned their losses due to the listing of blockbuster products
.
Taking Junshi Biotechnology as an example, in 2021, the company's revenue will increase by 152.
36% year-on-year due to the substantial growth in technology licensing revenue, the increase in franchise revenue, and the sales revenue brought by the commercialization of toripalimab injection in the domestic market.
Net profit has narrowed sharply year-on-year
.
The data shows that in 2021, Junshi Bio will achieve an operating income of 4.
025 billion yuan, a net profit loss of 721 million yuan, and a net loss of 1.
669 billion yuan in the same period last year
.
According to statistics, in 2021, the pace of domestic innovative drug listing will accelerate, and a total of 39 innovative drugs have been approved for marketing, many of which are products independently developed by China and have independent intellectual property rights
.
For example, the annual report of Zhenbao Island shows that in 2021, Zhenbao Island will have substantial progress in the research and development of innovative chemical drugs, innovative Chinese medicine drugs and in-hospital preparations, secondary development of advantageous varieties, and variety mergers and acquisitions.
During the reporting period, Zhenbao Island has three innovative traditional Chinese medicines.
Drugs, 4 innovative chemical drugs, and 41 generic chemical drug projects are promoted in coordination to form a cascaded supplementary product pipeline, laying a solid foundation for the company to continuously supply high-quality varieties to the market
.
In 2021, the company achieved operating income of 4.
127 billion yuan, a year-on-year increase of 21.
24%, and realized a net profit attributable to shareholders of the listed company of 332 million yuan
.
In 2021, Hengrui Medicine has achieved a lot of innovative achievements.
Its self-developed innovative drugs Haitrombopag ethanolamine tablets, Proline Henggliflozin tablets, and Dalcilis isethionate tablets have been approved for marketing, and the number of listed innovative drugs has increased to 10 More than 60 innovative drugs are under clinical development, and more than 250 clinical trials are being carried out at home and abroad
.
China's innovative drugs have entered the harvest period since 2018, and it is expected that more innovative drugs will be approved in the next 2-3 years
.
In 2022, the blockbuster varieties of many innovative pharmaceutical companies are expected to be approved for listing in China, and some loss-making bio-innovative drug companies are expected to quickly turn losses and increase their revenue volume after the launch of their blockbuster products
.
Among them, the class I innovative drug P-CAB tigora raw tablets (trade name: Taixinzan), which was independently developed and applied by Luoxin Pharmaceuticals, was approved by the State Drug Administration for the treatment of Reflux Esophagitis.
, referred to as RE)
.
This is the first national Class I innovative drug in Linyi, the first national Class I chemical innovative drug in Shandong Province, and a potassium ion-competitive acid blocker (P-CAB) developed by China
.
The industry predicts that 19 blockbuster new drugs will be approved in 2022, and two of the 19 innovative drugs will be independently developed by domestic pharmaceutical companies
.
Among them, kadonilimumab independently developed by Kangfang Bio is a bispecific antibody targeting PD-1 and CTLA-4.
Its main indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell carcinoma and nasopharyngeal carcinoma.
etc.
; Dozagliatin developed by Hua Medicine is a new type 2 diabetes drug developed by a domestic pharmaceutical company that has reached the primary efficacy endpoint, and is also a glucokinase activator (GKA) diabetes treatment that has submitted new drug marketing applications worldwide.
drug
.
With the accumulation of innovative drug R&D experience, innovative drug projects of domestic innovative pharmaceutical companies will continue to emerge
.
According to the industry, the continuous advancement of national centralized procurement will also force domestic pharmaceutical companies to accelerate their transformation from generic companies to innovative R&D companies.
A group of rapidly developing biopharmaceutical companies has gradually become a new force in China's pharmaceutical innovation
.
In 2022, China's pharmaceutical industry will also burst out with more new vitality
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
And some innovative pharmaceutical companies that are losing money have narrowed or even turned their losses due to the listing of blockbuster products
.
Taking Junshi Biotechnology as an example, in 2021, the company's revenue will increase by 152.
36% year-on-year due to the substantial growth in technology licensing revenue, the increase in franchise revenue, and the sales revenue brought by the commercialization of toripalimab injection in the domestic market.
Net profit has narrowed sharply year-on-year
.
The data shows that in 2021, Junshi Bio will achieve an operating income of 4.
025 billion yuan, a net profit loss of 721 million yuan, and a net loss of 1.
669 billion yuan in the same period last year
.
According to statistics, in 2021, the pace of domestic innovative drug listing will accelerate, and a total of 39 innovative drugs have been approved for marketing, many of which are products independently developed by China and have independent intellectual property rights
.
For example, the annual report of Zhenbao Island shows that in 2021, Zhenbao Island will have substantial progress in the research and development of innovative chemical drugs, innovative Chinese medicine drugs and in-hospital preparations, secondary development of advantageous varieties, and variety mergers and acquisitions.
During the reporting period, Zhenbao Island has three innovative traditional Chinese medicines.
Drugs, 4 innovative chemical drugs, and 41 generic chemical drug projects are promoted in coordination to form a cascaded supplementary product pipeline, laying a solid foundation for the company to continuously supply high-quality varieties to the market
.
In 2021, the company achieved operating income of 4.
127 billion yuan, a year-on-year increase of 21.
24%, and realized a net profit attributable to shareholders of the listed company of 332 million yuan
.
In 2021, Hengrui Medicine has achieved a lot of innovative achievements.
Its self-developed innovative drugs Haitrombopag ethanolamine tablets, Proline Henggliflozin tablets, and Dalcilis isethionate tablets have been approved for marketing, and the number of listed innovative drugs has increased to 10 More than 60 innovative drugs are under clinical development, and more than 250 clinical trials are being carried out at home and abroad
.
China's innovative drugs have entered the harvest period since 2018, and it is expected that more innovative drugs will be approved in the next 2-3 years
.
In 2022, the blockbuster varieties of many innovative pharmaceutical companies are expected to be approved for listing in China, and some loss-making bio-innovative drug companies are expected to quickly turn losses and increase their revenue volume after the launch of their blockbuster products
.
Among them, the class I innovative drug P-CAB tigora raw tablets (trade name: Taixinzan), which was independently developed and applied by Luoxin Pharmaceuticals, was approved by the State Drug Administration for the treatment of Reflux Esophagitis.
, referred to as RE)
.
This is the first national Class I innovative drug in Linyi, the first national Class I chemical innovative drug in Shandong Province, and a potassium ion-competitive acid blocker (P-CAB) developed by China
.
The industry predicts that 19 blockbuster new drugs will be approved in 2022, and two of the 19 innovative drugs will be independently developed by domestic pharmaceutical companies
.
Among them, kadonilimumab independently developed by Kangfang Bio is a bispecific antibody targeting PD-1 and CTLA-4.
Its main indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell carcinoma and nasopharyngeal carcinoma.
etc.
; Dozagliatin developed by Hua Medicine is a new type 2 diabetes drug developed by a domestic pharmaceutical company that has reached the primary efficacy endpoint, and is also a glucokinase activator (GKA) diabetes treatment that has submitted new drug marketing applications worldwide.
drug
.
With the accumulation of innovative drug R&D experience, innovative drug projects of domestic innovative pharmaceutical companies will continue to emerge
.
According to the industry, the continuous advancement of national centralized procurement will also force domestic pharmaceutical companies to accelerate their transformation from generic companies to innovative R&D companies.
A group of rapidly developing biopharmaceutical companies has gradually become a new force in China's pharmaceutical innovation
.
In 2022, China's pharmaceutical industry will also burst out with more new vitality
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
